Hold Rating for Aethlon Medical Amid Clinical and Financial Challenges

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Hold rating on Aethlon Medical today and set a price target of $1.50.

Swayampakula Ramakanth’s rating is based on several factors surrounding Aethlon Medical’s current clinical and financial status. The decision to focus on the Australian study and cancel plans for a similar study in India was driven by concerns over regulatory timelines, which could potentially delay clinical development. Although the initial cohort in Australia received positive feedback, the limited treatment exposure suggests that more data from subsequent cohorts will be necessary to draw meaningful conclusions about the efficacy of the Hemopurifier as an enhancer to anti-PD-1 therapy.
Financially, Aethlon reported no revenues and a net loss for the recent quarter, aligning with expectations. The company has limited cash reserves, which may necessitate additional fundraising efforts. The valuation of Aethlon’s stock is calculated using a risk-adjusted net present value analysis, considering various risks including clinical, commercial, and competitive factors. These elements contribute to the Hold rating, with a 12-month price target set at $1.50 per share.